Digital vasculopathy in systemic sclerosis (SSc) consists of a spectrum of Raynaud\'s phenomenon (RP), digital ulcers (DUs), critical digital ischaemia and escalation to gangrene. The complications of severe digital vasculopathy often require hospital-based management with intravenous therapies and surgery.[@R1] Although gangrene is not infrequent in the clinic, data on the prevalence and implications of gangrene in patients with SSc are scarce.[@R3] The DU Outcomes (DUO) Registry is a European, prospective, multicentre, observational cohort of patients with SSc and past and/or current DUs at enrolment.[@R8] The aims of the current study were (i) to describe the characteristics of an SSc--DU population according to the presence/history of gangrene and (ii) to identify the risk factors for the development of incident gangrene.

All patients in the participating centres with SSc and a history or presence of DUs are eligible for inclusion in the DUO Registry, irrespective of their treatment regimen. At enrolment, data were collected on demographic and clinical variables. Patients were categorised into three groups according to their past history of gangrene and current gangrene status at enrolment: 'never gangrene': no past and no current gangrene; 'ever gangrene': past and/or current gangrene; and 'current gangrene': gangrene reported at enrolment, irrespective of gangrene history (a subset of the 'ever gangrene' group).

Categorical variables were analysed using descriptive statistics. Potential risk factors for the development of incident gangrene in patients with ≥1 follow-up visit and no current gangrene at enrolment were analysed using univariable logistic regression (ULR) conducted on demographics, clinical variables and autoantibody measurements collected at enrolment. Multivariable logistic regression (MLR) using forward selection was conducted on patients with complete covariate information using those variables with a p value \<0.15 and sample size \>3000 from the ULR models, considering interdependency among similar factors.

Among the 4944 patients enrolled in the DUO Registry from April 2008 to November 2014, 4642 had information recorded on their gangrene status: 81.6% (n=3787) were categorised as 'never gangrene', 18.4% (n=855) as 'ever gangrene' and 5.6% (n=258) as 'current gangrene'. The three groups were generally similar regarding demographics and SSc characteristics, although more current smokers at enrolment were in the 'ever gangrene' and 'current gangrene' groups than in the 'never gangrene' group, and the 'current gangrene' group had the shortest time between first RP and enrolment ([table 1](#ANNRHEUMDIS2016209481TB1){ref-type="table"}). The proportion of patients with a history of DU-associated complications, interventions and hospitalisations was greater in the 'ever gangrene' group compared with the 'never gangrene' group.

###### 

Enrolment characteristics and patient demographics according to gangrene status\*

  -------------------------------------------------------------------------------------------------------------------------
                                                          Never^†^ gangrene\    Ever^‡^ gangrene\     Current gangrene\
                                                          (n=3787)              (n=855)               (n=258)^§^
  ------------------------------------------------------- --------------------- --------------------- ---------------------
  Gender                                                                                              

   Female, %                                              82.1                  77.7                  77.5

  Age at enrolment                                                                                    

   Mean (95% CI), years                                   54.4 (53.9 to 54.8)   54.8 (53.9 to 55.8)   52.8 (50.9 to 54.7)

  Smoking status                                                                                      

   n                                                      3386                  757                   233

   Current, %                                             14.4                  17.6                  24.0

   Former, %                                              23.3                  25.6                  17.6

   Never, %                                               62.3                  56.8                  58.4

  Pack-years of smoking                                                                               

   n                                                      868                   206                   73

   Mean (95% CI)                                          37.8 (31.3 to 44.3)   37.9 (27.5 to 48.4)   44.9 (24.9 to 64.9)

  Age at first RP                                                                                     

   n                                                      3409                  752                   229

   Mean (95% CI), years                                   41.3 (40.8 to 41.8)   40.7 (39.6 to 41.8)   41.2 (39.0 to 43.3)

  Age at first DU                                                                                     

   n                                                      3000                  700                   218

   Mean (95% CI), years                                   47.6 (47.1 to 48.2)   47.1 (45.9 to 48.2)   48.3 (46.1 to 50.5)

  SSc cutaneous subset                                                                                

   n                                                      3774                  850                   256

   Diffuse SSc, %                                         37.7                  32.0                  33.6

   Limited SSc, %                                         52.3                  58.2                  54.3

   Overlap, %                                             6.5                   6.0                   7.8

   Other, %                                               3.6                   3.8                   4.3

  Organ manifestations                                                                                

   n                                                      3787                  855                   258

   GI tract, %                                            54.0                  56.8                  46.5

   Lung fibrosis, %                                       40.4                  40.1                  38.0

   PAH, %                                                 12.1                  15.2                  13.2

   Heart, %                                               9.9                   10.9                  12.4

   Kidney, %                                              4.1                   6.0                   5.8

  Time from first RP to enrolment visit                                                               

   n                                                      3409                  752                   229

   Mean (95% CI), years                                   13.1 (12.8 to 13.5)   14.4 (13.6 to 15.3)   11.9 (10.4 to 13.5)

  Time from first DU to enrolment visit                                                               

   n                                                      3000                  700                   218

   Mean (95% CI), years                                   5.9 (5.7 to 6.2)      7.4 (6.8 to 8.0)      4.6 (3.8 to 5.5)

  Antibodies, n^1^/n^2^ (%)                                                                           

   ACA                                                    1184/2942 (40.2)      303/668 (45.4)        88/216 (40.7)

   ANA                                                    3307/3511 (94.2)      750/785 (95.5)        226/238 (95.0)

   Anti-Scl 70                                            1397/3145 (44.4)      282/690 (40.9)        87/218 (39.9)

   Anti-U1 RNP                                            170/2158 (7.9)        52/470 (11.1)         17/151 (11.3)

   Anti-U3 RNP                                            59/1534 (3.8)         19/300 (6.3)          4/104 (3.8)

   RNA polymerase III                                     127/1584 (8.0)        25/323 (7.7)          6/103 (5.8)

  Employed/self-employed, n (%)                           983/2674 (36.8)       167/564 (29.6)        75/207 (36.2)

  History of complications/interventions, % (95% CI)^¶^                                               

   Critical digital ischaemia                             30.1 (28.5 to 31.8)   82.2 (78.6 to 85.4)   69.4 (61.6 to 76.4)

   Gangrene                                               --                    91.7 (89.7 to 93.5)   71.9 (65.9 to 77.4)

   Autoamputation                                         3.1 (2.6 to 3.7)      24.1 (21.2 to 27.2)   15.9 (11.6 to 21.1)

   Soft-tissue infection requiring systemic antibiotics   23.9 (22.5 to 25.3)   53.5 (49.9 to 57.0)   44.5 (38.1 to 51.1)

   Osteomyelitis                                          1.3 (0.9 to 1.7)      11.9 (9.7 to 14.3)    7.4 (4.4 to 11.4)

   Hospitalisations for DUs                               32.7 (31.2 to 34.2)   70.1 (66.9 to 73.2)   58.9 (52.5 to 65.2)

   Upper limb sympathectomy                               2.2 (1.8 to 2.7)      8.8 (6.9 to 10.9)     7.2 (4.2 to 11.2)

   Digital sympathectomy                                  1.4 (1.0 to 1.8)      4.8 (3.4 to 6.5)      3.4 (1.5 to 6.6)

   Arterial reconstruction                                0.7 (0.5 to 1.0)      2.1 (1.3 to 3.4)      4.3 (2.1 to 7.7)

   Arthrodesis                                            1.4 (1.0 to 1.9)      5.7 (4.1 to 7.6)      2.0 (0.5 to 4.9)

   Debridement                                            7.5 (6.6 to 8.4)      25.7 (22.5 to 29.1)   21.0 (15.6 to 27.2)

   Surgical amputation                                    2.4 (1.9 to 3.0)      34.0 (30.5 to 37.5)   18.9 (13.8 to 24.8)

   Use of parenteral prostanoids                          51.6 (49.9 to 53.2)   74.4 (71.2 to 77.4)   74.4 (68.3 to 79.8)

  Prior DUs, n^1^/n^2^ (%)                                3759/3787 (99.3)      852/855 (99.6)        255/258 (98.8)

  Ongoing medications, %                                                                              

   n                                                      3787                  855                   258

   Analgesics and anti-inflammatories                     52.4                  60.6                  65.1

   Immunosuppressants                                     33.5                  28.2                  29.5

   Systemic antibiotics                                   13.3                  19.6                  36.0

   ERAs                                                   39.9                  52.0                  50.4

   CCBs                                                   46.0                  52.5                  53.1

   Prostacyclins                                          35.0                  36.5                  51.9

   PDE-5i                                                 5.9                   7.6                   5.8

   Topical DU treatments                                  19.1                  24.4                  36.8

   Other medications                                      64.8                  74.2                  67.1

   ERA+PDE-5i                                             2.2                   3.3                   2.7

   ERA+prostacyclin                                       14.3                  18.5                  24.4

   PDE-5i+prostacyclin                                    1.7                   2.8                   3.1

   ERA+PDE-5i+prostacyclin                                0.8                   1.5                   1.6

   ERA only\*\*                                           24.1                  31.8                  24.8
  -------------------------------------------------------------------------------------------------------------------------

\*Only patients who provided information on gangrene status (n=4642/4944) were categorised.

^†^Patients with no past and no current gangrene.

^‡^Patients with past and/or current gangrene.

^§^Patients with current gangrene at enrolment. The current gangrene group is a subset of the 'ever gangrene' group.

^¶^Data include only patients who provided information on the given item.

\*\*Out of ERA, PDE-5i and prostacyclins, only ERA is ticked.

ACA, anticentromere antibody; ANA, antinuclear antibody; CCB, calcium channel blocker; DU, digital ulcer; ERA, endothelin receptor antagonist; GI, gastrointestinal; n^1^/n^2^, n patients tested positive/n patients who had the test done; PAH, pulmonary arterial hypertension; PDE-5i, phosphodiesterase-type 5 inhibitor; RNP, ribonucleic protein; RP, Raynaud\'s phenomenon; SSc, systemic sclerosis.

Overall, 3809 patients were eligible for inclusion in the ULR analysis; the final number of patients included in each ULR model varied depending on missing data ([table 2](#ANNRHEUMDIS2016209481TB2){ref-type="table"}A). On MLR analysis, being a current/former smoker, having ≥3 finger DUs, previous gangrene and previous upper limb sympathectomy were independent risk factors at enrolment for development of incident gangrene ([table 2](#ANNRHEUMDIS2016209481TB2){ref-type="table"}B).

###### 

Risk factors associated with the development of incident gangrene during the observation period

  Risk factor                                                     Incident gangrene n/N (%)   No incident gangrene, n/N (%)   OR (95% CI)           p Value\*
  --------------------------------------------------------------- --------------------------- ------------------------------- --------------------- -----------
  \(A\) *ULR (N=3809)*^†^                                         *N=243*                     *N=3566*                                              
  Female gender                                                   189/243 (77.8)              2938/3566 (82.4)                0.73 (0.53 to 1.01)   0.055
  Smoking status                                                                                                                                    
   Current                                                        45/205 (22.0)               438/3102 (14.1)                 1.91 (1.32 to 2.76)   \<0.001
   Former                                                         58/205 (28.3)               728/3102 (23.5)                 1.46 (1.04 to 2.04)   0.028
  Number of finger DUs at enrolment                                                                                                                 
   1--2                                                           89/236 (37.7)               1315/3546 (37.1)                1.27 (0.93 to 1.72)   0.132
   3+                                                             58/236 (24.6)               666/3546 (18.8)                 1.54 (1.09 to 2.17)   0.015
  Anti-Scl 70                                                     103/196 (52.6)              1279/2872 (44.5)                1.39 (1.04 to 1.87)   0.027
  Previous gangrene                                               96/229 (41.9)               404/3378 (12.0)                 4.75 (3.57 to 6.34)   \<0.0001
  Previous autoamputation                                         32/231 (13.9)               188/3386 (5.6)                  2.69 (1.78 to 4.04)   \<0.0001
  Previous soft-tissue infection requiring systemic antibiotics   94/222 (42.3)               933/3253 (28.7)                 1.76 (1.33 to 2.32)   \<0.0001
  Previous osteomyelitis                                          19/232 (8.2)                84/3367 (2.5)                   3.24 (1.19 to 5.47)   \<0.0001
  Ongoing autoamputation                                          6/242 (2.5)                 46/3552 (1.3)                   2.32 (0.97 to 5.57)   0.059
  Ongoing osteomyelitis                                           4/243 (1.6)                 24/3558 (0.7)                   2.36 (0.80 to 6.99)   0.121
  Previous hospitalisation(s) for DUs (at least 1 day)            144/231 (62.3)              1290/3385 (38.1)                2.49 (1.89 to 3.29)   \<0.0001
  Previous upper limb sympathectomy                               20/228 (8.8)                100/3345 (3.0)                  3.24 (1.94 to 5.40)   \<0.0001
  Previous digital sympathectomy                                  11/228 (4.8)                58/3341 (1.7)                   2.70 (1.38 to 5.31)   0.004
  Previous arterial reconstruction                                5/227 (2.2)                 21/3336 (0.6)                   3.43 (1.25 to 9.44)   0.017
  Not employed/self-employed                                      205/243 (84.4)              2687/3566 (75.4)                1.78 (1.22 to 2.61)   0.003
  \(B\) *MLR*^‡^*(N=2479)*                                        *N=157*                     *N=2322*                                              
  Observation time, mean (SD), weeks                              174.7 (78.7)                126.2 (78.9)                    1.03 (1.02 to 1.04)   \<0.0001
  Smoking status                                                                                                                                    
   Current                                                        27/157 (17.2)               311/2322 (13.4)                 1.72 (1.07 to 2.77)   0.025
   Former                                                         47/157 (29.9)               509/2322 (21.9)                 1.69 (1.14 to 2.51)   0.009
  Number of finger DUs at enrolment                                                                                                                 
   1--2                                                           60/157 (38.2)               951/2322 (41.0)                 1.35 (0.90 to 2.03)   0.144
   3+                                                             46/157 (29.3)               491/2322 (21.1)                 1.69 (1.09 to 2.62)   0.020
  Anti-Scl 70                                                     79/157 (50.3)               1031/2322 (44.4)                1.39 (0.99 to 1.96)   0.058
  Previous gangrene                                               63/157 (40.1)               244/2322 (10.5)                 4.67 (3.24 to 6.73)   \<0.0001
  Previous upper limb sympathectomy                               15/157 (9.6)                67/2322 (2.9)                   2.21 (1.15 to 4.27)   0.018

\*Wald χ^2^ test.

^†^For the ULR analysis, observation time was a fixed covariate in the model. Data are shown for variables having p\<0.15 and n\>3000 for the patients for whom information is available).

^‡^For the MLR analysis, observation time was forced into the model as a fixed covariate and not included by the forward selection procedure; variables were selected with a selection criterion of p=0.15. Data are shown for the subset of patients making up the final models (n=2479) to allow comparison with the full cohort.

ACA, anticentromere antibody; ANA, antinuclear antibody; DU, digital ulcer; MLR, multivariable logistic regression; PAH, pulmonary arterial hypertension; RNP, ribonucleic protein; ULR, univariable logistic regression.

This analysis was the largest to date describing an SSc--DU population according to the presence/history of gangrene at enrolment and risk factors for incident gangrene during follow-up. It has demonstrated that, in current practice, gangrene is still a common event occurring in 18% of patients with SSc--DUs. Participating centres involved in the DUO Registry are specialist centres for the management of SSc--DUs; this may be selective for patients with more severe vascular disease, and therefore more prevalent gangrene. Multivariate analyses indicated that, in patients with no current gangrene, along with previous gangrene, being a current/former smoker, having ≥3 DUs and previous upper limb sympathectomy were independent risk factors at enrolment for developing incident gangrene. These results will help to risk-stratify patients with SSc--DUs and to evaluate preventive gangrene management strategies.
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